Académique Documents
Professionnel Documents
Culture Documents
N OVAK
tsnovak@yahoo.com
Business Development
Complex Negotiations
Operational Metrics
Lean Six Sigma Methodology
Marketing Campaigns
Strategic Planning
Inspirational Leadership
Client Relationships
PROFESSIONAL EXPERIENCE
PERNIX THERAPEUTICS, INC., Morristown, NJ
Chief Operating Officer
As a member of Executive Team, oversaw day-to-day quality, regulatory, and clinical operations for specialty
pharmaceutical company, designing and implementing business strategies, plans, and procedures.
Improved operational efficiency, developing and executing five-year strategic plan to integrate key
operational and business processes, resulting in six-fold increase in EBITDA after 12 months.
Strengthened marketing and business development efforts leading to four-fold increase in proposals,
100% increase in new business wins, and 28% increase in revenue.
Launched new India-based clinical research division to expand service offerings.
Led strategic growth initiatives, developing seven-year strategic plan leading to successful round of
financing from major banks.
Developed successful marketing initiatives and business plans, securing $68M in funding to acquire
publicly traded pharmaceutical company.
Forged partnerships with key external stakeholders, forming five-member board of directors.
TERENCE S. NOVAK
(862) 207-1262tsnovak@yahoo.com
Spearheaded operational and P&L responsibility for $250M pharmaceutical finished-dose contract
manufacturing business in North America, including five manufacturing facilities in the United
States, Canada, and Puerto Rico.
Drove implementation of Lean Six Sigma programs and consistent business metrics at all sites,
developing five-year strategic business plan that improved cost of goods and operational metrics.
Reversed Puerto Rican operations from eight quarters of negative profit to first profitable quarter.
Managed quality improvements, reorganizing sales, marketing, and account management operations
to increase new proposals by 80% and new business awards by 35%.
Held global operational and P&L responsibility for large and small molecule pharmaceutical contract
manufacturing and development business with 1000 employees and $200M in revenue.
Led multidisciplinary team in developing five-year strategic plan, resulting in increased revenue of
20% and EBITDA of 75%.
Directed strategic growth opportunities, identifying and executing joint venture to develop and
market sterile injectable products.
Prior experience includes positions as senior vice president for DSM Pharmaceuticals, responsible for building newly
created division; vice president of Cytogen Corporation, responsible for developing and executing sales and marketing
plan for oncology business unit; and executive vice president of Algos Pharmaceutical, responsible for start-up pain
management specialty company.